Revvity SG&A Expenses 2010-2024 | RVTY

Revvity sg&a expenses for the twelve months ending December 31, 2024 were $0.994B, a 2.78% decline year-over-year.

  • Revvity annual sg&a expenses for 2024 were $0.994B, a 2.78% decline from 2023.
  • Revvity annual sg&a expenses for 2023 were $1.023B, a 0.29% decline from 2022.
  • Revvity annual sg&a expenses for 2022 were $1.026B, a 5.16% increase from 2021.

Revvity SG&A Expenses 2010-2024 | RVTY

  • Revvity annual sg&a expenses for 2024 were $0.994B, a 2.78% decline from 2023.
  • Revvity annual sg&a expenses for 2023 were $1.023B, a 0.29% decline from 2022.
  • Revvity annual sg&a expenses for 2022 were $1.026B, a 5.16% increase from 2021.
Related Stocks
Company NameMarket
Cap
Danaher (DHR)$150.2B
Elevance Health (ELV)$90.6B
CVS Health (CVS)$82.1B
Cencora (COR)$47.2B
DiDi Global (DIDIY)$23.3B
Natera (NTRA)$22.2B
ICON (ICLR)$16.7B
BioMerieux (BMXMF)$14.1B
Doximity (DOCS)$14B
Viatris (VTRS)$13.2B
Solventum (SOLV)$12.9B
Avantor (AVTR)$11.9B
CochLear (CHEOY)$11.3B
Medpace Holdings (MEDP)$10.5B
EUROFINS SCIENT (ERFSF)$9.8B
HealthEquity (HQY)$9.7B
Sonic Healthcare (SKHHY)$8.7B
Charles River Laboratories (CRL)$8.3B
Amplifon S.p.A (AMFPF)$6.2B
Bausch + Lomb (BLCO)$5.6B
Organon (OGN)$4B
Sotera Health (SHC)$3.8B
BrightSpring Health Services (BTSG)$3.6B
Surgery Partners (SGRY)$3.3B
Concentras Parent (CON)$3B
GeneDx Holdings (WGS)$2.8B
Alignment Healthcare (ALHC)$2.8B
Teladoc Health (TDOC)$2.2B
Ardent Health Partners (ARDT)$2.1B
Progyny (PGNY)$2B